The genomic landscape of two Burkitt lymphoma cases and derived cell lines: comparison between primary and relapse samples

References

• Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin’s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. JCO. 1998;16:2780–2795.
   PubMed Web of Science ®Google Scholar
• Magrath I, Adde M, Shad A, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol. 1996;14:925–934.
   PubMed Web of Science ®Google Scholar
• Lacasce A, Howard O, Lib S, et al. Modified Magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity. Leuk Lymphoma. 2004;45:761–767.
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Pittaluga S, Shovlin M, et al. Low-intensity therapy in adults with Burkitt's lymphoma. N Engl J Med. 2013;369:1915–1925.
   PubMed Web of Science ®Google Scholar
• Thomas DA, Faderl S, O'Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006;106:1569–1580.
   PubMed Web of Science ®Google Scholar
• Barnes JA, Lacasce AS, Feng Y, et al. Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis. Ann Oncol. 2011;22:1859–1864.
   PubMed Web of Science ®Google Scholar
• Costa LJ, Xavier AC, Wahlquist AE, et al. Trends in survival of patients with Burkitt lymphoma/leukemia in the USA: an analysis of 3691 cases. Blood. 2013;121:4861–4866.
   PubMed Web of Science ®Google Scholar
• Sweetenham JW, Pearce R, Taghipour G, et al. Adult Burkitt's and Burkitt-like non-Hodgkin's lymphoma-outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse: results from the European Group for Blood and Marrow Transplantation. J Clin Oncol. 1996;14:2465–2472.
   PubMed Web of Science ®Google Scholar
• Peniket AJ, Ruiz de Elvira MC, Taghipour G, et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant. 2003;31:667–678.
   PubMed Web of Science ®Google Scholar
• Blum KA, Lozanski G, Byrd JC. Adult Burkitt leukemia and lymphoma. Blood. 2004;104:3009–3020.
   PubMed Web of Science ®Google Scholar
• Young RM, Staudt LM. Targeting pathological B cell receptor signaling in lymphoid malignancies. Nat Rev Drug Discov. 2013;12:229–243.
   PubMed Web of Science ®Google Scholar
• Schmitz R, Young RM, Ceribelli M, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature. 2012;490:116–120.
   PubMed Web of Science ®Google Scholar
• Zech L, Haglund U, Nilsson K, et al. Characteristic chromosomal abnormalities in biopsies and lymphoid-cell lines from patients with Burkitt and non-Burkitt lymphomas. Int J Cancer. 1976;17:47–56.
   PubMed Web of Science ®Google Scholar
• Dalla-Favera R, Bregni M, Erikson J, et al. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci USA. 1982;79:7824–7827.
   PubMed Web of Science ®Google Scholar
• Felsher DW, Zetterberg A, Zhu J, et al. Overexpression of MYC causes p53-dependent G2 arrest of normal fibroblasts. Proc Natl Acad Sci USA. 2000;97:10544–10548.
   PubMed Web of Science ®Google Scholar
• Richter J, Schlesner M, Hoffmann S, et al. Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat Genet. 2012;44:1316–1320.
   PubMed Web of Science ®Google Scholar
• Hemann MT, Bric A, Teruya-Feldstein J, et al. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature. 2005;436:807–811.
   PubMed Web of Science ®Google Scholar
• Hoffman B, Liebermann DA. Apoptotic signaling by c-MYC. Oncogene. 2008;27:6462–6472.
   PubMed Web of Science ®Google Scholar
• Cato MH, Chintalapati SK, Yau IW, et al. Cyclin D3 is selectively required for proliferative expansion of germinal center B cells. Mol Cell Biol. 2011;31:127–137.
   PubMed Web of Science ®Google Scholar
• Peled JU, Yu JJ, Venkatesh J, et al. Requirement for cyclin D3 in germinal center formation and function. Cell Res. 2010;20:631–646.
   PubMed Web of Science ®Google Scholar
• Love C, Sun Z, Jima D, et al. The genetic landscape of mutations in Burkitt lymphoma. Nat Genet. 2012;44:1321–1325.
   PubMed Web of Science ®Google Scholar
• Sander S, Calado DP, Srinivasan L, et al. Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis. Cancer Cell. 2012;22:167–179.
   PubMed Web of Science ®Google Scholar
• Lowe SW, Ruley HE, Jacks T, et al. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 1993;74:957–967.
   PubMed Web of Science ®Google Scholar
• Malina A, Mills JR, Cencic R, et al. Repurposing CRISPR/Cas9 for in situ functional assays. Genes Dev. 2013;27:2602–2614.
   PubMed Web of Science ®Google Scholar
• Morin RD, Assouline SE, Alcaide M, et al. Genetic landscapes of relapsed and refractory diffuse large B cell lymphomas. Clin Cancer Res. 2015;22:2290–2300.
   PubMed Web of Science ®Google Scholar
• Okosun J, Bödör C, Wang J, et al. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat Genet. 2014;46:176–181.
   PubMed Web of Science ®Google Scholar
• Aukema SM, Theil L, Rohde M, et al. Sequential karyotyping in Burkitt lymphoma reveals a linear clonal evolution with increase in karyotype complexity and a high frequency of recurrent secondary aberrations. Br J Haematol. 2015;170:814–825.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–2390.
   PubMed Web of Science ®Google Scholar
• Gavino C, Cotter A, Lichtenstein D, et al. CARD9 deficiency and spontaneous central nervous system candidiasis: complete clinical remission With GM-CSF therapy. Clin Infect Dis. 2014;59:81–84.
   PubMed Web of Science ®Google Scholar
• van Dongen JJM, Lhermitte L, Bottcher S, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia. 2012;26:1908–1975.
   PubMed Web of Science ®Google Scholar
• McGowan-Jordan J, Simons A, Schmid MM, et al. In: McGowan-Jordan J, Simons A, Schmid MM, editors. ISCN: an international system for human cytogenomic nomenclature. Basel, Switzerland; New York: Karger; 2016.
   Google Scholar
• Brown JR, Byrd JC, Coutre SE, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia. Blood. 2014;123:3390–3397.
   PubMed Web of Science ®Google Scholar
• Thudium K, Gallo J, Bouillaud E, et al. Bioavailability of everolimus administered as a single 5 mg tablet versus five 1 mg tablets: a randomized, open-label, two-way crossover study of healthy volunteers. Clin Pharmacol: Adv Appl. 2015;7:11–17.
   PubMedGoogle Scholar
• Embree L, Gelmon K, Tolcher A, et al. Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injection. Cancer Chemother Pharmacol. 1998;41:347–352.
   PubMed Web of Science ®Google Scholar
• Mazur L, Opydo-Chanek M, Stojak M, et al. Mafosfamide as a new anticancer agent: preclinical investigations and clinical trials. Anticancer Res. 2012;32:2783–2789.
   PubMed Web of Science ®Google Scholar
• Kaul S, Igwemezie LN, Stewart DJ, et al. Pharmacokinetics and bioequivalence of etoposide following intravenous administration of etoposide phosphate and etoposide in patients with solid tumors. J Clin Oncol. 1995;13:2835–2841.
   PubMed Web of Science ®Google Scholar
• Ryan J, Montero J, Rocco J, et al. iBH3: simple, fixable BH3 profiling to determine apoptotic priming in primary tissue by flow cytometry. Biol Chem. 2016;397:671–678.
   PubMed Web of Science ®Google Scholar
• Yee KW, Zeng Z, Konopleva M, et al. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res. 2006;12:5165–5173.
   PubMed Web of Science ®Google Scholar
• Wall M, Poortinga G, Stanley KL, et al. The mTORC1 inhibitor everolimus prevents and treats Emu-Myc lymphoma by restoring oncogene-induced senescence. Cancer Discov. 2013;3:82–95.
   PubMed Web of Science ®Google Scholar
• Pasqualucci L, Neumeister P, Goossens T, et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature. 2001;412:341–346.
   PubMed Web of Science ®Google Scholar
• Cesarman E, Dalla-Favera R, Bentley D, et al. Mutations in the first exon are associated with altered transcription of c-myc in Burkitt lymphoma. Science. 1987;238:1272–1275.
   PubMed Web of Science ®Google Scholar
• Bahram F, von der Lehr N, Cetinkaya C, et al. c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover. Blood. 2000;95:2104–2110.
   PubMed Web of Science ®Google Scholar
• Hanel W, Marchenko N, Xu S, et al. Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis. Cell Death Differ. 2013;20:898–909.
   PubMed Web of Science ®Google Scholar
• Song H, Hollstein M, Xu Y. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nat Cell Biol. 2007;9:573–580.
   PubMed Web of Science ®Google Scholar
• Kai X, Chellappa V, Donado C, et al. IkappaB kinase beta (IKBKB) mutations in lymphomas that constitutively activate canonical nuclear factor kappaB (NFkappaB) signaling. J Biol Chem. 2014;289:26960–26972.
   PubMed Web of Science ®Google Scholar
• Irving J, Matheson E, Minto L, et al. Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition. Blood. 2014;124:3420–3430.
   PubMed Web of Science ®Google Scholar
• Jeong SM, Xiao C, Finley LW, et al. SIRT4 has tumor-suppressive activity and regulates the cellular metabolic response to DNA damage by inhibiting mitochondrial glutamine metabolism. Cancer Cell. 2013;23:450–463.
   PubMed Web of Science ®Google Scholar
• Hodson DJ, Janas ML, Galloway A, et al. Deletion of the RNA-binding proteins ZFP36L1 and ZFP36L2 leads to perturbed thymic development and T lymphoblastic leukemia. Nat Immunol. 2010;11:717–724.
   PubMed Web of Science ®Google Scholar
• Forero-Castro M, Robledo C, Lumbreras E, et al. The presence of genomic imbalances is associated with poor outcome in patients with Burkitt lymphoma treated with dose-intensive chemotherapy including rituximab. Br J Haematol. 2016;172:428–438.
   PubMed Web of Science ®Google Scholar
• Sekimizu M, Mori T, Kikuchi A, et al. Prognostic impact of cytogenetic abnormalities in children and adolescents with mature B-cell non-Hodgkin lymphoma: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG). Pediatr Blood Cancer. 2015;62:1294–1296.
   PubMed Web of Science ®Google Scholar
• Onciu M, Schlette E, Zhou Y, et al. Secondary chromosomal abnormalities predict outcome in pediatric and adult high-stage Burkitt lymphoma. Cancer. 2006;107:1084–1092.
   PubMed Web of Science ®Google Scholar
• Muzio G, Maggiora M, Paiuzzi E, et al. Aldehyde dehydrogenases and cell proliferation. Free Radic Biol Med. 2012;52:735–746.
   PubMed Web of Science ®Google Scholar
• Zhang X, Lu X, Akhter S, et al. FANCI is a negative regulator of Akt activation. Cell Cycle. 2016;15:1134–1143.
   PubMed Web of Science ®Google Scholar
• Soengas MS, Capodieci P, Polsky D, et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature. 2001;409:207–211.
   PubMed Web of Science ®Google Scholar
• Soengas MS, Alarcon RM, Yoshida H, et al. Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. Science. 1999;284:156–159.
   PubMed Web of Science ®Google Scholar
• Brimmell M, Mendiola R, Mangion J, et al. BAX frameshift mutations in cell lines derived from human haemopoietic malignancies are associated with resistance to apoptosis and microsatellite instability. Oncogene. 1998;16:1803–1812.
   PubMed Web of Science ®Google Scholar
• Chumduri C, Gillissen B, Richter A, et al. Apoptosis resistance, mitotic catastrophe, and loss of ploidy control in Burkitt lymphoma. J Mol Med. 2015;93:559–572.
   PubMed Web of Science ®Google Scholar
• Chen CH, Cruz LA, Mochly-Rosen D. Pharmacological recruitment of aldehyde dehydrogenase 3A1 (ALDH3A1) to assist ALDH2 in acetaldehyde and ethanol metabolism in vivo. Proc Natl Acad Sci USA. 2015;112:3074–3079.
   PubMed Web of Science ®Google Scholar
• Yan J, De Melo J, Cutz JC, et al. Aldehyde dehydrogenase 3A1 associates with prostate tumorigenesis. Br J Cancer. 2014;110:2593–2603.
   PubMed Web of Science ®Google Scholar
• Sreerama L, Sladek NE. Primary breast tumor levels of suspected molecular determinants of cellular sensitivity to cyclophosphamide, ifosfamide, and certain other anticancer agents as predictors of paired metastatic tumor levels of these determinants. Rational individualization of cancer chemotherapeutic regimens. Cancer Chemother Pharmacol. 2001;47:255–262.
   PubMed Web of Science ®Google Scholar
• Lambert S, Davis JQ, Bennett V. Morphogenesis of the node of Ranvier: co-clusters of ankyrin and ankyrin-binding integral proteins define early developmental intermediates. J Neurosci. 1997;17:7025–7036.
   PubMed Web of Science ®Google Scholar
• Zou H, Henzel WJ, Liu X, et al. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell. 1997;90:405–413.
   PubMed Web of Science ®Google Scholar
• Hahn C, Hirsch B, Jahnke D, et al. Three new types of Apaf-1 in mammalian cells. Biochem Biophys Res Commun. 1999;261:746–749.
   PubMed Web of Science ®Google Scholar
• Fujimoto A, Takeuchi H, Taback B, et al. Allelic imbalance of 12q22-23 associated with APAF-1 locus correlates with poor disease outcome in cutaneous melanoma. Cancer Res. 2004;64:2245–2250.
   PubMed Web of Science ®Google Scholar
• Kuo L, Freed EO. ARRDC1 as a mediator of microvesicle budding. Proc Natl Acad Sci USA. 2012;109:4025–4026.
   PubMed Web of Science ®Google Scholar
• Martins VR, Dias MS, Hainaut P. Tumor-cell-derived microvesicles as carriers of molecular information in cancer. Curr Opin Oncol. 2013;25:66–75.
   PubMed Web of Science ®Google Scholar
• Wang Q, Liu X, Tang N, et al. GASZ promotes germ cell derivation from embryonic stem cells. Stem Cell Res. 2013;11:845–860.
   PubMed Web of Science ®Google Scholar
• Yan W, Rajkovic A, Viveiros MM, et al. Identification of Gasz, an evolutionarily conserved gene expressed exclusively in germ cells and encoding a protein with four ankyrin repeats, a sterile-alpha motif, and a basic leucine zipper. Mol Endocrinol (Baltimore, MD). 2002;16:1168–1184.
   PubMedGoogle Scholar
• Kwasnicka-Crawford DA, Carson AR, Roberts W, et al. Characterization of a novel cation transporter ATPase gene (ATP13A4) interrupted by 3q25–q29 inversion in an individual with language delay. Genomics. 2005;86:182–194.
   PubMed Web of Science ®Google Scholar
• Takagi T, Inoue H, Takahashi N, et al. Sulforaphene attenuates multinucleation of pre-osteoclasts by suppressing expression of cell-cell fusion-associated genes DC-STAMP, OC-STAMP, and Atp6v0d2. Biosci Biotechnol Biochem. 2017;30:1–4.
   Google Scholar
• Huang SL, Chao CC. Silencing of taxol-sensitizer genes in cancer cells: lack of sensitization effects. Cancers (Basel). 2015;7:1052–1071.
   PubMed Web of Science ®Google Scholar
• Sato T, Sato M, Kiyohara K, et al. Molecular cloning and characterization of a novel human beta1,3-glucosyltransferase, which is localized at the endoplasmic reticulum and glucosylates O-linked fucosylglycan on thrombospondin type 1 repeat domain. Glycobiology. 2006;16:1194–1206.
   PubMed Web of Science ®Google Scholar
• Radziwill G, Erdmann RA, Margelisch U, et al. The Bcr kinase downregulates Ras signaling by phosphorylating AF-6 and binding to its PDZ domain. Mol Cell Biol. 2003;23:4663–4672.
   PubMed Web of Science ®Google Scholar
• Shtivelman E, Lifshitz B, Gale RP, et al. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature. 1985;315:550–554.
   PubMed Web of Science ®Google Scholar
• Cisternas FA, Vincent JB, Scherer SW, et al. Cloning and characterization of human CADPS and CADPS2, new members of the Ca2+-dependent activator for secretion protein family. Genomics. 2003;81:279–291.
   PubMed Web of Science ®Google Scholar
• Tallila J, Jakkula E, Peltonen L, et al. Identification of CC2D2A as a Meckel syndrome gene adds an important piece to the ciliopathy puzzle. Am J Hum Genet. 2008;82:1361–1367.
   PubMed Web of Science ®Google Scholar
• Kitchens RL. Role of CD14 in cellular recognition of bacterial lipopolysaccharides. CD14 in the inflammatory response. Vol. 74. Karger Publishers; 1999. p. 61–82.
   Google Scholar
• Cheah MT, Chen JY, Sahoo D, et al. CD14-expressing cancer cells establish the inflammatory and proliferative tumor microenvironment in bladder cancer. Proc Natl Acad Sci USA. 2015;112:4725–4730.
   PubMed Web of Science ®Google Scholar
• Helman LJ, Ahn TG, Levine MA, et al. Molecular cloning and primary structure of human chromogranin A (secretory protein I) cDNA. J Biol Chem. 1988;263:11559–11563.
   PubMed Web of Science ®Google Scholar
• Burgio SL, Conteduca V, Menna C, et al. Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone. Endocrine-Relat Cancer. 2014;21:487–493.
   PubMed Web of Science ®Google Scholar
• Ma Z, Tsuchiya N, Yuasa T, et al. Clinical significance of polymorphism and expression of chromogranin a and endothelin-1 in prostate cancer. J Urol. 2010;184:1182–1188.
   PubMed Web of Science ®Google Scholar
• Zhong Z, Ohnmacht J, Reimer MM, et al. Chondrolectin mediates growth cone interactions of motor axons with an intermediate target. J Neurosci. 2012;32:4426–4439.
   PubMed Web of Science ®Google Scholar
• Masuda K, Takano A, Oshita H, et al. Chondrolectin is a novel diagnostic biomarker and a therapeutic target for lung cancer. Clin Cancer Res. 2011;17:7712–7722.
   PubMed Web of Science ®Google Scholar
• Gumienny TL, Brugnera E, Tosello-Trampont AC, et al. CED-12/ELMO, a novel member of the CrkII/Dock180/Rac pathway, is required for phagocytosis and cell migration. Cell. 2001;107:27–41.
   PubMed Web of Science ®Google Scholar
• Fan W, Yang H, Xue H, et al. ELMO3 is a novel biomarker for diagnosis and prognosis of non-small cell lung cancer. Int J Clin Exp Pathol. 2015;8:5503–5508.
   PubMedGoogle Scholar
• Kristensen LS, Soes S, Hansen LL. ELMO3: a direct driver of cancer metastasis? Cell Cycle. 2014;13:2483–2484.
   PubMed Web of Science ®Google Scholar
• Castella M, Jacquemont C, Thompson EL, et al. FANCI regulates recruitment of the FA core complex at sites of DNA damage independently of FANCD2. PLoS Genet. 2015;11:e1005563.
   PubMed Web of Science ®Google Scholar
• Benayoun BA, Dipietromaria A, Bazin C, et al. FOXL2: at the crossroads of female sex determination and ovarian function. Forkhead transcription factors. Springer; 2009. p. 207–226.
   Google Scholar
• Liu X-L, Meng Y-H, Wang J-L, et al. FOXL2 suppresses proliferation, invasion and promotes apoptosis of cervical cancer cells. Int J Clin Exp Pathol. 2014;7:1534–1543.
   PubMed Web of Science ®Google Scholar
• Ross V, Board P. Molecular cloning and heterologous expression of an alternatively spliced human Mu class glutathione S-transferase transcript. Biochem J. 1993;294:373–380.
   PubMed Web of Science ®Google Scholar
• Matthias C, Bockmühl U, Jahnke V, et al. Polymorphism in cytochrome P450 CYP2D6, CYP1A1, CYP2E1 and glutathione S-transferase, GSTM1, GSTM3, GSTT1 and susceptibility to tobacco-related cancers: studies in upper aerodigestive tract cancers. Pharmacogenet Genomics. 1998;8:91–100.
   Google Scholar
• Mercurio F, Zhu H, Murray BW, et al. IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation. Science. 1997;278:860–866.
   PubMed Web of Science ®Google Scholar
• Haas M, Ward DC, Lee J, et al. Localization of Shaw-related K + channel genes on mouse and human chromosomes. Mamm Genome. 1993;4:711–715.
   PubMed Web of Science ®Google Scholar
• Zhong WX, Wang YB, Peng L, et al. Lanthionine synthetase C-like protein 1 interacts with and inhibits cystathionine beta-synthase: a target for neuronal antioxidant defense. J Biol Chem. 2012;287:34189–34201.
   PubMed Web of Science ®Google Scholar
• Chang H, Jeung H-C, Jung JJ, et al. Identification of genes associated with chemosensitivity to SAHA/taxane combination treatment in taxane-resistant breast cancer cells. Breast Cancer Res Treat. 2011;125:55–63.
   PubMed Web of Science ®Google Scholar
• Zondag GC, Koningstein GM, Jiang YP, et al. Homophilic interactions mediated by receptor tyrosine phosphatases mu and kappa. A critical role for the novel extracellular MAM domain. J Biol Chem. 1995;270:14247–14250.
   PubMed Web of Science ®Google Scholar
• Meng L, Xu Y, Xu C, et al. Biomarker discovery to improve prediction of breast cancer survival: using gene expression profiling, meta-analysis, and tissue validation. OTT. 2016;9:6177–6185.
   Google Scholar
• Kelly K, Cochran BH, Stiles CD, et al. Cell-specific regulation of the c-myc gene by lymphocyte mitogens and platelet-derived growth factor. Cell. 1983;35(3 Pt 2):603–610.
   Web of Science ®Google Scholar
• Armelin HA, Armelin MC, Kelly K, et al. Functional role for c-myc in mitogenic response to platelet-derived growth factor. Nature. 1984;310:655–660.
   PubMed Web of Science ®Google Scholar
• Cowling VH, Turner SA, Cole MD. Burkitt's lymphoma-associated c-Myc mutations converge on a dramatically altered target gene response and implicate Nol5a/Nop56 in oncogenesis. Oncogene. 2014;33:3519–3527.
   PubMed Web of Science ®Google Scholar
• Bae YK, Shimizu T, Muraoka O, et al. Expression of sax1/nkx1.2 and sax2/nkx1.1 in zebrafish. Gene Expr Patterns. 2004;4:481–486.
   PubMed Web of Science ®Google Scholar
• Yamada G, Kioussi C, Schubert FR, et al. Regulated expression of Brachyury(T), Nkx1.1 and Pax genes in embryoid bodies. Biochem Biophys Res Commun. 1994;199:552–563.
   PubMed Web of Science ®Google Scholar
• Malnic B, Godfrey PA, Buck LB. The human olfactory receptor gene family. Proc Natl Acad Sci USA. 2004;101:2584–2589.
   PubMed Web of Science ®Google Scholar
• Van Ziffle J, Yang W, Chehab FF. Homozygous deletion of six olfactory receptor genes in a subset of individuals with Beta-thalassemia. PLoS One. 2011;6:e17327.
   PubMed Web of Science ®Google Scholar
• Dupont N, Chauhan S, Arko-Mensah J, et al. Neutral lipid stores and lipase PNPLA5 contribute to autophagosome biogenesis. Curr Biol. 2014;24:609–620.
   PubMed Web of Science ®Google Scholar
• Kumar A, Bhandari A, Sarde SJ, et al. Understanding V(D)J recombination initiator RAG1 gene using molecular phylogenetic and genetic variant analyses and upgrading missense and non-coding variants of clinical importance. Biochem Biophys Res Commun. 2015;462:301–313.
   PubMed Web of Science ®Google Scholar
• Mendes RD, Sarmento LM, Cante-Barrett K, et al. PTEN microdeletions in T-cell acute lymphoblastic leukemia are caused by illegitimate RAG-mediated recombination events. Blood. 2014;124:567–578.
   PubMed Web of Science ®Google Scholar
• Mathias RA, Greco TM, Oberstein A, et al. Sirtuin 4 is a lipoamidase regulating pyruvate dehydrogenase complex activity. Cell. 2014;159:1615–1625.
   PubMed Web of Science ®Google Scholar
• Bloch DB, Nakajima A, Gulick T, et al. Sp110 localizes to the PML-Sp100 nuclear body and may function as a nuclear hormone receptor transcriptional coactivator. Mol Cell Biol. 2000;20:6138–6146.
   PubMed Web of Science ®Google Scholar
• Thanmalagan RR, Naorem LD, Venkatesan A. Expression data analysis for the identification of potential biomarker of pregnancy associated breast cancer. Pathol Oncol Res. 2017;23:537–544.
   PubMed Web of Science ®Google Scholar
• Awate S, De Benedetti A. TLK1B mediated phosphorylation of Rad9 regulates its nuclear/cytoplasmic localization and cell cycle checkpoint. BMC Mol Biol. 2016;17:3.
   PubMed Web of Science ®Google Scholar
• Takayama Y, Kokuryo T, Yokoyama Y, et al. Silencing of Tousled-like kinase 1 sensitizes cholangiocarcinoma cells to cisplatin-induced apoptosis. Cancer Lett. 2010;296:27–34.
   PubMed Web of Science ®Google Scholar
• Li Y, DeFatta R, Anthony C, et al. A translationally regulated Tousled kinase phosphorylates histone H3 and confers radioresistance when overexpressed. Oncogene. 2001;20:726–738.
   PubMed Web of Science ®Google Scholar
• Norton KS, McClusky D, Sen S, et al. TLK1B is elevated with eIF4E overexpression in breast cancer. J Surg Res. 2004;116:98–103.
   PubMed Web of Science ®Google Scholar
• Levine RD, Kinsey JL. On the repulsion of energy eigenstates in the time domain. Proc Natl Acad Sci USA. 1991;88:11133–11137.
   PubMed Web of Science ®Google Scholar
• Muller PA, Vousden KH. p53 mutations in cancer. Nat Cell Biol. 2013;15:2–8.
   PubMed Web of Science ®Google Scholar
• Goll MG, Kirpekar F, Maggert KA, et al. Methylation of tRNAAsp by the DNA methyltransferase homolog Dnmt2. Science. 2006;311:395–398.
   PubMed Web of Science ®Google Scholar
• Elhardt W, Shanmugam R, Jurkowski TP, et al. Somatic cancer mutations in the DNMT2 tRNA methyltransferase alter its catalytic properties. Biochimie. 2015;112:66–72.
   PubMed Web of Science ®Google Scholar
• MacKenzie PI, Rogers A, Elliot DJ, et al. The novel UDP glycosyltransferase 3A2: cloning, catalytic properties, and tissue distribution. Mol Pharmacol. 2011;79:472–478.
   PubMed Web of Science ®Google Scholar
• Huizing M, Didier A, Walenta J, et al. Molecular cloning and characterization of human VPS18, VPS 11, VPS16, and VPS33. Gene. 2001;264:241–247.
   PubMed Web of Science ®Google Scholar
• Choi B, Heo JH, Kwon HJ, et al. Tocotrienols enhance melanosome degradation through endosome docking/fusion proteins in B16F10 melanoma cells. Food Funct. 2013;4:1481–1488.
   Web of Science ®Google Scholar
• Zhang F, Yu X. WAC, a functional partner of RNF20/40, regulates histone H2B ubiquitination and gene transcription. Mol Cell. 2011;41:384–397.
   PubMed Web of Science ®Google Scholar
• Ding L, Ley TJ, Larson DE, et al. Clonal evolution in relapsed acute myeloid leukemia revealed by whole genome sequencing. Nature. 2012;481:506–510.
   PubMed Web of Science ®Google Scholar
• Vogel KU, Bell LS, Galloway A, et al. The RNA-binding proteins Zfp36l1 and Zfp36l2 enforce the thymic beta-selection checkpoint by limiting DNA damage response signaling and cell cycle progression. JI. 2016;197:2673–2685.
   Google Scholar
• Yonemori K, Seki N, Kurahara H, et al. ZFP36L2 promotes cancer cell aggressiveness and is regulated by antitumor microRNA-375 in pancreatic ductal adenocarcinoma. Cancer Sci. 2017;108:124–135.
   PubMed Web of Science ®Google Scholar
• Fujii Y, Kakegawa M, Koide H, et al. Zfp296 is a novel Klf4-interacting protein and functions as a negative regulator. Biochem Biophys Res Commun. 2013;441:411–417.
   PubMed Web of Science ®Google Scholar
• Poland KS, Shardy DL, Azim M, et al. Overexpression of ZNF342 by juxtaposition with MPO promoter/enhancer in the novel translocation t(17;19)(q23;q13.32) in pediatric acute myeloid leukemia and analysis of ZNF342 expression in leukemia. Genes Chromosom Cancer. 2009;48:480–489.
   PubMed Web of Science ®Google Scholar
• Morin RD, Mendez-Lago M, Mungall AJ, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011;476:298–303.
   PubMed Web of Science ®Google Scholar